臨床外科67巻11号

2012年10月発行

特集 外科医のための癌診療データ

臓器別最新データ 7．胆道癌

胆道癌の非切除・再発例

著者： 古瀬純司¹ 成毛大輔¹ 有馬志穂¹ 春日章良¹ 北村浩¹ 高須充子¹ 長島文夫¹

所属機関： ¹杏林大学医学部内科学腫瘍内科

ページ範囲：P.207 - P.213

文献概要

覚えておきたいデータ

◆胆道癌の術後再発時期は3年以内が多く，再発部位としては肝，腹膜，局所再発が多い．

◆非切除例および術後再発例に対する治療はゲムシタビン＋シスプラチン併用療法が標準治療である．ゲムシタビン単独との比較試験では生存期間中央値は11～12か月である．

◆術後フォローアップの方法としてはCEAおよびCA19-9の腫瘍マーカーと造影CTが基本であり，3か月ごとに実施することが勧められる．

◆今後，ゲムシタビン＋S-1併用療法やゲムシタビン＋S-1＋シスプラチン併用療法，さらに2次治療や分子標的薬の開発が期待される．

参考文献

1）日本胆道外科研究会（編）：外科・病理　胆道癌取扱い規約．第4版．金原出版，1997，pp30-39

2）Sobin LH, Gospodarowicz MK, Wittekind CH（eds）：TNM Classification of Malignant Tumours. 7th ed. Wiley-Liss, New York, 2009, pp114-131

3）がんの統計'11：http://ganjoho.jp/public/statistics/backnumber/2011_jp.html（2012年5月3日アクセス）

4）Nagakawa T, Kayahara M, Ikeda S, et al：Biliary tract cancer treatment：results from the Biliary Tract Cancer Statistics Registry in Japan. J Hepatobiliary Pancreat Surg 9：569-575, 2002

5）Nimura Y, Kamiya J, Kondo S, et al：Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma：Nagoya experience. J Hepatobiliary Pancreat Surg 7：155-162, 2000

6）Jang JY, Kim SW, Park DJ, et al：Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg 241：77-84, 2005

7）Murakami Y, Uemura K, Sudo T, et al：Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg 250：950-956, 2009

8）Cho SY, Kim SH, Park SJ, et al：Center for Liver Cancer, National Cancer Center, Gyeonggi-do, Republic of Korea. Adjuvant chemoradiation therapy in gallbladder cancer. J Surg Oncol 102：87-93, 2010

9）Murakami Y, Uemura K, Sudo T, et al：Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol 18：651-658, 2011

10）Crane CH, Macdonald KO, Vauthey JN, et al：Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys 53：969-974, 2002

11）Shinohara ET, Mitra N, Guo M, et al：Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas. Int J Radiat Oncol Biol Phys 74：1191-1198, 2009

12）Glimelius B, Hoffman K, Sjoden PO, et al：Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7：593-600, 1996

13）Sharma A, Dwary AD, Mohanti BK, et al：Best supportive care compared with chemotherapy for unresectable gall bladder cancer：a randomized controlled study. J Clin Oncol 28：4581-4586, 2010

14）Valle JW, Wasan H, Johnson P, et al：Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours：a multicentre randomised phase Ⅱ study-The UK ABC-01 Study. Br J Cancer 101：621-627, 2009

15）Valle J, Wasan H, Palmer DH, et al：Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362：1273-1281, 2010

16）Okusaka T, Nakachi K, Fukutomi A, et al：Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer：a comparative multicentre study in Japan. Br J Cancer 103：469-474. 2010

17）Ikeda M, Okusaka T, Ueno H, et al：A phase Ⅱ trial of Uracil-tegafur（UFT）in patients with advanced biliary tract carcinoma. Jpn J Clin Oncol 35：439-443, 2005

18）Furuse J, Okusaka T, Ohkawa S, et al：A phase Ⅱ study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. Cancer Chemother Pharmacol 65：113-120, 2009

19）Okusaka T, Ishii H, Funakoshi A, et al：phase Ⅱ study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 57：647-653, 2006

20）Furuse J, Okusaka T, Boku N, et al：S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer：a multicenter phase Ⅱ study. Cancer Chemother Pharmacol 62：849-855, 2008

21）Knox JJ, Hedley D, Oza A, et al：Combining gemcitabine and capecitabine in patients with advanced biliary cancer：a phase Ⅱ trial. J Clin Oncol 23：2332-2338, 2005

22）Cho JY, Paik YH, Chang YS, et al：Capecitabine combined with gemcitabine（CapGem）as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 104：2753-2758, 2005

23）Sasaki T, Isayama H, Nakai Y, et al：Multicenter, phase Ⅱ study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 65：1101-1107, 2010

24）Harder J, Riecken B, Kummer O, et al：Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 95：848-852, 2006

25）André T, Reyes-Vidal JM, Fartoux L, et al：Gemcitabine and oxaliplatin in advanced biliary tract carcinoma：a phase Ⅱ study. Br J Cancer 99：862-867, 2008

26）Kim YJ, Im SA, Kim HG, et al：A phase Ⅱ trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. Ann Oncol 19：99-103, 2008

27）Yamashita Y, Taketomi A, Itoh S, et al：phase Ⅱ trial of gemcitabine combined with 5-fluorouracil and cisplatin（GFP）chemotherapy in patients with advanced biliary tree cancers Jpn J Clin Oncol 40：24-28, 2010

28）Morizane C, Okusaka T, Mizusawa J, et al：Randomized phase Ⅱ trial of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer：Results of the Japan Clinical Oncology Group study（JCOG0805）. 2012 Gastrointestinal Cancers Symposium. J Clin Oncol 30：2012（suppl 4；abstr 255）

29）Furuse J, Okusaka T, Bridgewater J, et al：Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. Crit Rev Oncol Hematol 80：31-39, 2011

30）Oh SY, Jeong CY, Hong SC, et al：phase Ⅱ study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs 29：1066-1072, 2011

31）Sasaki T, Isayama H, Nakai Y, et al：Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Invest New Drugs 29：1488-1493, 2011

32）Suzuki E, Ikeda M, Okusaka T, et al：A multicenter phase Ⅱ study of S-1 in gemcitabine-refractory biliary tract cancer. J Clin Oncol 28：2010（supple；abstr 4145）

33）Sasaki T, Isayama H, Nakai Y, et al：Multicenter phase Ⅱ study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 30：708-713, 2012

34）Philip PA, Mahoney MR, Allmer C et al：phase Ⅱ study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24：3069-3074, 2006

35）Ramanathan RK, Belani CP, Singh DA, et al：A phase Ⅱ study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 64：777-783, 2009

36）Bengala C, Bertolini F, Malavasi N, et al：Sorafenib in patients with advanced biliary tract carcinoma：a phase Ⅱ trial. Br J Cancer 102：68-72, 2010

37）El-Khoueiry AB, Rankin CJ, Ben-Josef E, et al：SWOG 0514：a phase Ⅱ study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs 30：1646-1651, 2012

38）Bekaii-Saab T, Phelps MA, Li X, et al：Multi-institutional phase Ⅱ study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 29：2357-2363, 2011

39）Lubner SJ, Mahoney MR, Kolesar JL, et al：Report of a multicenter phase Ⅱ trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer：a phase Ⅱ Consortium study. J Clin Oncol 28：3491-3497, 2010

40）Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al：Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome：a phase 2 study. Lancet Oncol 11：48-54, 2010

41）Gruenberger B, Schueller J, Heubrandtner U, et al：Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer：a phase 2 study. Lancet Oncol 11：1142-1148, 2010

42）Lee J, Park SH, Chang HM, et al：Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer：a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 13：181-188, 2012